Study guide
15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid
Key Takeaways Explain This Topic AI
Diabetic ketoacidosis is defined by blood glucose above 11 mmol/L (or known diabetes), ketones of at least 3.0 mmol/L and either a pH below 7.3 or bicarbonate below 15 mmol/L; treatment is fluid, a fixed-rate insulin infusion of 0.1 units/kg/h and potassium replacement.
The hyperosmolar hyperglycaemic state features marked hyperglycaemia (often above 30 mmol/L), osmolality above 320 mOsm/kg and severe dehydration without significant ketosis, and carries a high thrombosis risk.
Thyroid storm presents with hyperthermia, tachycardia, agitation and heart failure; treat with beta-blockade, propylthiouracil or carbimazole, iodine given at least 1 hour after the thionamide, hydrocortisone, cooling and supportive care.
Adrenal crisis is treated with hydrocortisone 100 mg intravenously followed by 200 mg over 24 hours (infusion or 50 mg every 6 hours) with intravenous fluids.
Phaeochromocytoma requires alpha-blockade (phenoxybenzamine or doxazosin) for about 10-14 days before beta-blockade, and hypotension and hypoglycaemia often follow tumour removal.
Last updated: October 2026
15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid
- Diabetes Mellitus
- Preoperative Assessment
Type of diabetes and treatment, glycaemic control ( HbA1c ), hypoglycaemia awareness, and end-organ damage: ischaemic heart disease (often silent), nephropathy, autonomic neuropathy (gastroparesis, postural hypotension, cardiac instability) and stiff joint syndrome (difficult laryngoscopy).
UK guidance suggests optimising control before elective surgery when HbA1c is above about 69 mmol/mol (8.5%) .
Perioperative Management
Aim for capillary glucose of about 6-10 mmol/L (up to 12 mmol/L acceptable), checked at least hourly during surgery.
Short starvation (one missed meal): adjust oral agents and insulin, schedule first on the list.
Longer starvation or poor control: variable-rate intravenous insulin infusion with a glucose-containing fluid (for example 5% glucose in 0.45% saline with potassium), and continue basal long-acting insulin at about 80% of the usual dose.
Autonomic neuropathy increases aspiration risk and haemodynamic instability.
Diabetic Emergencies
- Feature Diabetic ketoacidosis (DKA) Hyperosmolar hyperglycaemic state (HHS)
- Typical patient Type 1 (any age) Older, type 2
- Onset Hours to a day Days
- Glucose Above 11 mmol/L (may be normal in euglycaemic DKA) Often above 30 mmol/L
- Ketones At least 3.0 mmol/L (or urine 2+) Below 3.0 mmol/L
- pH / bicarbonate pH below 7.3 or bicarbonate below 15 mmol/L pH above 7.3, bicarbonate above 15 mmol/L
- Osmolality Variable Above 320 mOsm/kg
Main risks Cerebral oedema (children), hypokalaemia, hypoglycaemia during treatment Thrombosis, osmotic demyelination with rapid sodium shifts, high mortality
DKA Treatment (Adult)
Fluids: 0.9% saline, for example 1 L over the first hour, then guided by response; add 10% glucose when glucose falls below 14 mmol/L while continuing insulin.
Fixed-rate insulin infusion: 0.1 units/kg/h ; continue long-acting basal insulin.
Potassium: total body potassium is depleted even when plasma levels are normal; add 40 mmol/L to fluids when potassium is 3.5-5.5 mmol/L.
Treat the precipitant (infection, missed insulin, myocardial infarction).
Resolution: ketones below 0.6 mmol/L and venous pH above 7.3.
Bicarbonate is not routinely given.
Euglycaemic DKA
SGLT2 inhibitors (dapagliflozin, empagliflozin) can cause ketoacidosis with near-normal glucose, especially with fasting, surgery and dehydration. Check ketones in any unwell patient on these drugs; treat with insulin plus glucose. This is why SGLT2 inhibitors are withheld before surgery.
HHS Treatment
Slow correction: 0.9% saline to restore volume, aiming for a gradual fall in osmolality (about 3-8 mOsm/kg/h) and sodium (no more than 10 mmol/L in 24 hours). Insulin at a lower fixed rate (about 0.05 units/kg/h) is started only once glucose stops falling with fluids alone, unless ketones are significantly raised. Give prophylactic low molecular weight heparin.
- Thyroid Disease
- Hyperthyroidism
Make the patient euthyroid before elective surgery with carbimazole or propylthiouracil and beta-blockers.
Large goitres may compress or deviate the trachea; assess with imaging and consider awake techniques if there is airway compromise.
After thyroidectomy: haemorrhage with airway compression (remove sutures/clips at the bedside), recurrent laryngeal nerve injury (bilateral injury causes stridor), and hypocalcaemia from parathyroid damage.
Thyroid Storm
A life-threatening exacerbation precipitated by surgery, infection or stopping treatment in a poorly controlled patient. Features: hyperthermia above 40 °C, tachycardia and atrial fibrillation, heart failure, agitation, vomiting and diarrhoea. It can mimic malignant hyperthermia, but rigidity and the rapid rise in end-tidal carbon dioxide are less prominent.
Treatment:
Beta-blockade: propranolol or esmolol (also reduces T4-to-T3 conversion).
Thionamide: propylthiouracil (preferred, also blocks peripheral conversion) or carbimazole.
Iodine (Lugol's solution or potassium iodide) at least 1 hour after the thionamide, so it is not used as substrate for new hormone.
Hydrocortisone (reduces conversion and treats relative adrenal insufficiency).
Cooling, fluids, treat the precipitant; avoid aspirin (displaces T4 from binding proteins).
Hypothyroidism
Patients are sensitive to sedatives and anaesthetic agents, may have hypothermia, hyponatraemia, bradycardia, reduced cardiac output and delayed gastric emptying. Elective surgery should wait for replacement. Myxoedema coma is treated with intravenous levothyroxine or liothyronine, hydrocortisone first (adrenal insufficiency may coexist), and supportive care.
- Adrenal Disease
- Adrenal Insufficiency
Primary (Addison's disease): destruction of the adrenal cortex; both cortisol and aldosterone are lost (hyponatraemia, hyperkalaemia, pigmentation).
Secondary: pituitary failure or, most commonly, suppression by exogenous glucocorticoids; aldosterone is preserved.
Perioperative steroid cover (Association of Anaesthetists 2020 guidance) for patients on at least 5 mg prednisolone daily (or equivalent) for at least 4 weeks: hydrocortisone 100 mg at induction, then 200 mg per 24 hours by infusion (or 50 mg every 6 hours) until eating and drinking, then double the usual oral dose for about 48 hours (minor surgery) or up to a week (major surgery).
Adrenal crisis: hypotension refractory to vasopressors, hyponatraemia, hyperkalaemia, hypoglycaemia, abdominal pain. Treat with hydrocortisone 100 mg intravenously immediately , then 200 mg per 24 hours, with intravenous fluids and glucose.
Cushing's Syndrome
Hypertension, diabetes, obesity, fragile skin and veins, osteoporosis (care with positioning), hypokalaemia and obstructive sleep apnoea.
Conn's Syndrome
Primary hyperaldosteronism causes hypertension and hypokalaemia with metabolic alkalosis; correct potassium with spironolactone before surgery.
Phaeochromocytoma
A catecholamine-secreting tumour of adrenal medullary chromaffin cells (extra-adrenal tumours are paragangliomas). Diagnosis: plasma or urinary metanephrines , then imaging.
Preoperative Preparation
Alpha-blockade first: phenoxybenzamine (non-competitive, irreversible) or doxazosin (competitive alpha-1) for about 10-14 days , with liberal salt and fluid intake to restore plasma volume.
Beta-blockade only after alpha-blockade , to control tachycardia; beta-blockade alone leaves unopposed alpha-stimulation and can cause a hypertensive crisis and heart failure.
Targets (Roizen criteria, for example): blood pressure below about 160/90 mmHg, orthostatic hypotension, and few ventricular ectopics.
Intraoperative Management
Invasive arterial monitoring before induction; avoid drugs that release histamine or catecholamines (morphine, atracurium in large doses, ketamine, ephedrine, metoclopramide, droperidol).
Hypertensive surges during tumour handling: phentolamine, sodium nitroprusside, glyceryl trinitrate, magnesium sulphate , esmolol or clevidipine.
After venous ligation: profound hypotension from loss of catecholamines and residual alpha-blockade (treat with fluids, noradrenaline, vasopressin) and rebound hypoglycaemia as insulin suppression ends; monitor glucose for 24-48 hours.
Carcinoid Syndrome
Neuroendocrine tumours, usually of the small bowel, secrete serotonin, histamine, kallikrein and bradykinin . The syndrome (flushing, diarrhoea, bronchospasm) usually indicates hepatic metastases, because the liver otherwise inactivates the mediators. Carcinoid heart disease affects right-sided valves (tricuspid regurgitation, pulmonary stenosis).
Octreotide (somatostatin analogue) prevents and treats carcinoid crises: give preoperatively and intravenously during surgery (for example 50-100 μ g \mu\text{g} μ g boluses).
Avoid histamine-releasing drugs and catecholamines where possible, because catecholamines can trigger mediator release; if a vasopressor is needed, vasopressin or phenylephrine may be preferred, with octreotide.